Where now for anti-EGF receptor therapies in colorectal cancer?

References

• Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis. Colon Rectum40(1), 15–24 (1997).
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Conley BA, Allegra C et al. Clinical trial designs for predictive marker validation in cancer treatment trials. J. Clin. Oncol.23(9), 2020–2027 (2005).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol.22(7), 1201–1208 (2004).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan – refractory metastatic colorectal cancer. N. Engl. J. Med.351(4), 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Burstein HJ. The distinctive nature of HER2-positive breast cancers. N. Engl. J. Med.353(16), 1652–1654 (2005).
   PubMed Web of Science ®Google Scholar
• Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol.23(9), 1803–1810 (2005).
   PubMed Web of Science ®Google Scholar
• Etienne-Grimaldi MC, Cayre A, Penault-Llorca F et al. EGFR expression in colon cancer: a break in the clouds. Ann. Oncol.17(12), 1850–1851 (2006).
   PubMedGoogle Scholar
• Francoual M, Etienne-Grimaldi MC, Formento JL et al. EGFR in colorectal cancer: more than a simple receptor. Ann. Oncol.17(6), 962–967 (2006).
   PubMed Web of Science ®Google Scholar
• Adams RA, Smith CS, Wilson RH et al; on behalf of the MRC COIN Trial Investigators. Epidermal growth factor receptor (EGFR) as a predictive and prognostic marker in patients with advanced colorectal cancer (aCRC): the MRC COIN trial experience. ASCO 2011 Gastrointestinal Cancers Symposium 2011: J. Clin. Oncol.29(Suppl. 4), (2011) (Abstract 359).
   Google Scholar
• Barber TD, Vogelstein B, Kinzler KW et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med.351(27), 2883 (2004).
   PubMed Web of Science ®Google Scholar
• Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol.6(5), 279–286 (2005).
   PubMed Web of Science ®Google Scholar
• Lenz HJ, Van Cutsem E, Khambata-Ford S et al. Multicenter Phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol.24(30), 4914–4921 (2006).
   PubMed Web of Science ®Google Scholar
• Siena S, Sartore-Bianchi A, Di Nicolantonio F et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl Cancer Inst.101(19), 1308–1324 (2009).
   PubMedGoogle Scholar
• Shia J, Klimstra DS, Li AR et al. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod. Pathol.18(10), 1350–1356 (2005).
   PubMed Web of Science ®Google Scholar
• Spindler KL, Lindebjerg J, Nielsen JN et al. Epidermal growth factor receptor analyses in colorectal cancer: a comparison of methods. Int. J. Oncol.29(5), 1159–1165 (2006).
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol.25(22), 3230–3237 (2007).
   PubMed Web of Science ®Google Scholar
• Jacobs B, De Roock W, Piessevaux H et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol.27(30), 5068–5074 (2009).
   PubMed Web of Science ®Google Scholar
• Tabernero J, Cervantes A, Rivera F et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a Phase I dose-escalation study. J. Clin. Oncol.28(7), 1181–1189 (2011).
   Google Scholar
• Baker JB, Dutta D, Watson D et al. Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br. J. Cancer104, 488–495 (2011).
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol.26(14), 2311–2319 (2008).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med.360(14), 1408–1417 (2009).
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O’Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med.357(20), 2040–2048 (2007).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol.25(13), 1658–1664 (2007).
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res.66(8), 3992–3995 (2006).
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol.26(10), 1626–1634 (2008).
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med.359(17), 1757–1765 (2008).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol.27(5), 663–671 (2009).
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J et al. Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol.28(31), 4697–4705 (2010).
   PubMed Web of Science ®Google Scholar
• Peeters M, Price TJ, Cervantes A et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol.28(31), 4706–4713 (2010).
   PubMed Web of Science ®Google Scholar
• Seymour MT. Addition of panitumumab to irinotecan: results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). J. Clin. Oncol.29(Suppl.), (2011) (Abstract 3523).
   Google Scholar
• Kohne CH, Rougier, P, Stroh C et al. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC), a meta-analysis of the CRYSTAL and OPUS studies according to K-RAS and BRAF mutation status. Presented at: Gastrointestinal Cancers Symposium. CA, USA, 21–22 January 2011.
   Google Scholar
• Maughan TS, Adams RA, Smith CS et al. Identification of potentially responsive subsets when cetuximab is added to oxaliplatin–fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): mature results of the MRC COIN trial. J. Clin. Oncol.28(Suppl. 15s), (2010) (Abstract 3502).
   PubMedGoogle Scholar
• Adams RA, Meade AM, Madi A et al. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br. J. Cancer100(2), 251–258 (2009).
   PubMed Web of Science ®Google Scholar
• Ochenduszko SL, Krzemieniecki K. Targeted therapy in advanced colorectal cancer: more data, more questions. Anticancer Drugs21(8), 737–748 (2010).
   PubMed Web of Science ®Google Scholar
• Maughan TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised Phase 3 MRC COIN trial. Lancet377(9783), 2103–2114 (2011).
   PubMed Web of Science ®Google Scholar
• De Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA304(16), 1812–1820 (2010).
   PubMed Web of Science ®Google Scholar
• Tejpar S, Bokemeyer C, Celik I et al. Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab. J. Clin. Oncol.29(Suppl.), (2011) (Abstract 3511).
   PubMedGoogle Scholar
• De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol.11(8), 753–762 (2010).
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Martini M, Molinari F A et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol.26(35), 5705–5712 (2008).
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Martini M, Molinari F et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res.69(5), 1851–1857 (2009).
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Sartore-Bianchi A, Molinari F et al. BRAF, PIK3CA and KRAS mutations and loss of PTEN expression impair response to EGFR targeted therapies in metastatic colorectal cancer. Am. Assoc. Cancer Res.68, 1953 (2009).
   Google Scholar
• Yokota T, Ura T, Shibata D et al. Evaluation of BRAF mutation as a powerful prognostic factor in advanced and recurrent colorectal cancer. Presented at: Gastrointestinal Cancers Symposium. CA, USA, 21–22 January 2011.
   Google Scholar
• Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol.29(15), 2011–2019 (2011).
   PubMed Web of Science ®Google Scholar
• Tejpar S, Popovici V, Delorenzi M et al. Mutant KRAS and BRAF gene expression profiles in colorectal cancer: results of the translational study on the PETACC 3-EORTC 40993-SAKK 60–00 trial. J. Clin. Oncol.28(15 Suppl.), (2010) (Abstract 3505).
   PubMedGoogle Scholar
• Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev.27(2), 253–261 (2008).
   PubMed Web of Science ®Google Scholar
• De Roock SF, Biesmans B, Jacobs B et al. DUSP expression as a predictor of outcome after cetuximab treatment in Kras wild type and mutant colorectal tumors. Presented at: Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 17–19 January 2009.
   Google Scholar
• Souglakos J, Philips J, Wang R et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br. J. Cancer101(3), 465–472 (2009).
   PubMed Web of Science ®Google Scholar
• Sangale Z, Prass C, Carlson A et al. A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl. Immunohistochem. Mol. Morphol.19(2), 173–183 (2010).
   Google Scholar
• Russo A, Bazan V, Iacopetta B et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J. Clin. Oncol.23(30), 7518–7528 (2005).
   PubMed Web of Science ®Google Scholar
• Di Fiore F, Blanchard F, Oden-Gangloff A et al. TP53 mutations in irinotecan-refractory KRAS wt-BRAF wt metastatic colorectal cancer patients treated with cetuximab-based chemotherapy. J. Clin. Oncol.29(Suppl. 4), (2011) (Abstract 426).
   Google Scholar
• Shaw P. Anti Epidermal Growth Factor Therapy Modelled in The Mouse. Cardiff University, Cardiff, Wales, UK (2010).
   Google Scholar
• Saif MW, Kaley K, Chu E et al. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clin. Colorectal Cancer5(5), 315–318 (2008).
   Google Scholar
• Rubin BP, Duensing A. Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Lab. Ivest. J. Tech. Methods Pathol.86(10), 981–986 (2006).
   PubMed Web of Science ®Google Scholar
• Paule B, Castagne V, Picard V et al. MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. Med. Oncol.27(4), 1066–1072 (2011).
   Google Scholar
• Wheeler DL, Huang S, Kruser TJ et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene27(28), 3944–3956 (2008).
   PubMed Web of Science ®Google Scholar
• Shankaran H, Wiley HS, Resat H. Receptor downregulation and desensitization enhance the information processing ability of signalling receptors. BMC Syst. Biol.1, 48 (2007).
   PubMed Web of Science ®Google Scholar
• Hyun TS, Rao DS, Saint-Dic D et al. HIP1 and HIP1r stabilize receptor tyrosine kinases and bind 3-phosphoinositides via epsin N-terminal homology domains. J. Biol. Chem.279(14), 14294–14306 (2004).
   PubMed Web of Science ®Google Scholar
• Hyun TS, Ross TS. HIP1: trafficking roles and regulation of tumorigenesis. Trends Mol. Med.10(4), 194–199 (2004).
   PubMed Web of Science ®Google Scholar
• Nevo J, Mattila E, Pellinen T et al. Mammary-derived growth inhibitor alters traffic of EGFR and induces a novel form of cetuximab resistance. Clin. Cancer Res.15(21), 6570–6581 (2009).
   PubMed Web of Science ®Google Scholar
• Sok JC, Coppelli FM, Thomas SM et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin. Cancer Res.12(17), 5064–5073 (2006).
   PubMed Web of Science ®Google Scholar
• Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Rev.9(7), 463–475 (2009).
   Google Scholar
• Lee D, Yu M, Lee E et al. Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. J. Clin. Invest.119(9), 2702–2713 (2009).
   PubMed Web of Science ®Google Scholar
• Sergina NV, Rausch M, Wang D et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature445(7126), 437–441 (2007).
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Mandolesi A, Giampieri R et al. The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. Oncologist16(1), 53–60 (2011).
   PubMed Web of Science ®Google Scholar
• Kountourakis P, Pavlakis K, Psyrri A et al. Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer6, 46 (2006).
   PubMed Web of Science ®Google Scholar
• Valabrega G, Montemurro F, Sarotto I et al. TGFα expression impairs trastuzumab-induced HER2 downregulation. Oncogene24(18), 3002–3010 (2005).
   PubMed Web of Science ®Google Scholar
• Li C, Iida M, Dunn EF, Ghia AJ et al. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene28(43), 3801–3813 (2009).
   PubMed Web of Science ®Google Scholar
• Shanmugam C, Jhala NC, Katkoori VR et al. Prognostic value of mucin 4 expression in colorectal adenocarcinomas. Cancer116(15), 3577–3586 (2010).
   PubMed Web of Science ®Google Scholar
• Price-Schiavi SA, Jepson S, Li P et al. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int. J. Cancer99(6), 783–791 (2002).
   PubMed Web of Science ®Google Scholar
• Weber MM, Fottner C, Liu SB et al. Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer95(10), 2086–2095 (2002).
   PubMed Web of Science ®Google Scholar
• Buck E, Eyzaguirre A, Rosenfeld-Franklin M et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res.68(20), 8322–8332 (2008).
   PubMed Web of Science ®Google Scholar
• Guix M, Faber AC, Wang SE et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest.118(7), 2609–2619 (2008).
   PubMed Web of Science ®Google Scholar
• Lu Y, Zi X, Zhao Y et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (herceptin). J. Natl Cancer Inst.93(24), 1852–1857 (2001).
   PubMed Web of Science ®Google Scholar
• Dallas NA, Xia L, Fan F et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res.69(5), 1951–1957 (2009).
   PubMed Web of Science ®Google Scholar
• Levy EM, Sycz G, Arriaga JM et al. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells. Innate Immunity15(2), 91–100 (2009).
   PubMedGoogle Scholar
• Chen LF, Cohen EE, Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin. Cancer Res.16(9), 2489–2495 (2011).
   Google Scholar
• Geva R. An international consortium study in chemorefractory metastatic colorectal cancer patients to assess the impact of FCGR polymorphisms on cetuximab efficacy. J. Clin. Oncol.29(Suppl.), (2011) (Abstract 3528).
   PubMedGoogle Scholar
• Shepard HM, Brdlik CM, Schreiber H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J. Clin. Invest.118(11), 3574–3581 (2008).
   PubMed Web of Science ®Google Scholar
• Meng J, Peng H, Dai B et al. High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol. Ther.8(21), 2073–2080 (2009).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Viciana P, Warne PH, Dhand R et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature370(6490), 527–532 (1994).
   PubMed Web of Science ®Google Scholar
• Kim SM, Kim JS, Kim JH et al. Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells. Cancer Lett.296(2), 150–159 (2010).
   PubMed Web of Science ®Google Scholar
• Zuo Q, Shi M, Chen J et al. The Ras signaling pathway mediates cetuximab resistance in nasopharyngeal carcinoma. Biomed. Pharmacother.65(3), 168–174 (2011).
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med.355(26), 2733–2743 (2006).
   PubMed Web of Science ®Google Scholar
• Frank DJ, Brooks W, Kim et al. A Phase II trial of lapatinib and capecitabine for patients with refractory advanced colorectal adenocarcinoma. J. Clin. Oncol.28(Suppl.), (2010) (Abstract e14092).
   PubMedGoogle Scholar
• Haluska P, Carboni JM, TenEyck C et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol. Cancer Ther.7(9), 2589–2598 (2008).
   PubMed Web of Science ®Google Scholar
• Huang F, Greer A, Hurlburt W et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res.69(1), 161–170 (2009).
   PubMed Web of Science ®Google Scholar
• Kaulfuss S, Burfeind P, Gaedcke J et al. Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Mol. Cancer Ther.8(4), 821–833 (2009).
   PubMed Web of Science ®Google Scholar
• Reidy DL, Vakiani E, Fakih MG et al. Randomized, Phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J. Clin. Oncol.28(27), 4240–4246 (2011).
   Google Scholar
• Eng C. A randomized, Phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): primary and biomarker analyses. J. Clin. Oncol.29(Suppl.), (2011) (Abstract 3500).
   PubMedGoogle Scholar
• Viloria-Petit A, Crombet T, Jothy S et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res.61(13), 5090–5101 (2001).
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Bianco R, Caputo R et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin. Cancer Res.10(2), 784–793 (2004).
   PubMed Web of Science ®Google Scholar
• Hecht JR, Mitchell E, Chidiac T et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol.27(5), 672–680 (2009).
   PubMed Web of Science ®Google Scholar
• Punt C, Tol,J, Rodenburg, CJ et al. Randomized Phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J. Clin. Oncol.26(Suppl.), (2008) (Abstract LBA4011).
   Google Scholar
• Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med.360(6), 563–572 (2009).
   PubMed Web of Science ®Google Scholar
• Grothey A. EGFR antibodies in colorectal cancer: where do they belong? J. Clin. Oncol.28(31), 4668–4670 (2010).
   PubMed Web of Science ®Google Scholar
• Sharma M, Kozloff M. Modi SS et al. Dasatinib (D) in previously treated metastatic colorectal cancer (mCRC) patients: a Phase II trial of the University of Chicago Phase II consortium. Presented at: Gastrointestinal Cancers Symposium. CA, USA, 21–22 January 2011.
   Google Scholar
• Lieu CH, Wolff RA, Eng C et al. Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer. J. Clin. Oncol.28(Suppl. 15), (2010) (Abstract 3536).
   PubMedGoogle Scholar
• Strickler J. Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. J. Clin. Oncol.29(Suppl. 4), (2011) (Abstract 513).
   Google Scholar
• She QB, Halilovic E, Ye Q et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell18(1), 39–51 (2011).
   Google Scholar
• Chandarlapaty S, Sawai A, Scaltriti M et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell19(1), 58–71 (2011).
   PubMed Web of Science ®Google Scholar
• Serra V, Scaltriti M, Prudkin L et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene30(22), 2547–2557 (2011).
   PubMed Web of Science ®Google Scholar
• Oliveira S, Schiffelers RM, van der Veeken J et al. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J. Control Release145(2), 165–175 (2011).
   Google Scholar
• Cragg MS, Harris C, Strasser A et al. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat. Rev.9(5), 321–326 (2009).
   Google Scholar
• Cragg MS, Kuroda J, Puthalakath H et al. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med.4(10), 1681–1689; discussion 1690 (2007).
   PubMed Web of Science ®Google Scholar